Association Between Overall Survival and the Tendency for ...

由 A Melamed 著作 · 2021 · 被引用 22 次 — Some cancer programs now administer neoadjuvant chemotherapy to most patients with advanced ovarian cancer. To estimate the association between ...

由 SL Coleridge 著作 · 2021 · 被引用 50 次 — Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.

Several RCTs have demonstrated that IP/IV chemotherapy improves survival in optimally resected, stage III ovarian cancer, compared with IV chemotherapy alone.

由 S Sato 著作 · 2014 · 被引用 102 次 — On the basis of the clinical features, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is considered to be an alternative treatment ...

由 I Vergote 著作 · 2010 · 被引用 2565 次 — Neoadjuvant chemotherapy is not inferior to primary cytoreductive surgery for patients with stage IIIC or IV ovarian carcinoma. No significant ...

由 A Nikolaidi 著作 · 2022 · 被引用 11 次 — Neo-adjuvant chemotherapy (NACT) has been implemented mostly in treating advanced disease, with studies performed having numerous limitations.

由 A Nikolaidi 著作 · 2022 · 被引用 11 次 — Neo-adjuvant chemotherapy (NACT) has been implemented mostly in treating advanced disease, with studies performed having numerous limitations.

Patient selection and approach to neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer. Formulary drug information for this topic.